DJIA 17,039.49 60.36 0.36%
NASDAQ 4,532.10 5.62 0.12%
S&P 500 1,992.37 5.86 0.29%
market minute promo


4.20 -0.04 (-0.94%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $4.20 -0.94%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.26
Previous Close $4.24
Daily Range $4.18 - $4.33
52-Week Range $4.06 - $12.95
Market Cap $434.5M
P/E Ratio -4.08
Dividend (Yield) $0.00 (0.0%)
Volume 1,007,877
Average Daily Volume 1,414,364
Current FY EPS -$0.97





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

The Implications of Obesity as a Disability in Europe

Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).

Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind

Arena And VIVUS: A Case Study In Small-Cap Pharma

Belviq Sales Flatten Out But Edge Above Qsymia

FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another

The 52-Week Low Club for Wednesday

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog

Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog

VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog

Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain

Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog

Vivus Beats The Street - Still Has A Loss

See More VVUS News...

VVUS's Top Competitors

VVUS $4.20 (-0.94%)
Current stock: VVUS
NVS $88.95 (0.40%)
Current stock: NVS
RHHBY $36.44 (-0.02%)
Current stock: RHHBY
PFE $28.82 (-0.24%)
Current stock: PFE